SynthesisThoracic cancer2022
MicroRNA-21 was a promising biomarker for lung carcinoma diagnosis: An update meta-analysis.
Synthesis in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.
- Identification of microbial markers associated with lung cancer based on multi-cohort 16 s rRNA analyses: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- MicroRNA-21 was a promising biomarker for lung carcinoma diagnosis: An update meta-analysis.Thoracic cancer · 2022Pooled it
- Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.Cancers · 2023Review
- Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic performance of microRNA-21 detected in serum or sputum as a biomarker for lung carcinoma identification through pooling the open published data.
methodsClinical diagnostic studies related to microRNA-21 as a biomarker for lung carcinoma identification were electronically searched in the databases of Pubmed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, and Google Scholar. The data of the included studies was extracted and made pooling of diagnostic sensitivity, specificity, diagnostic odds ratio (DOR), area under the summary receiver operating characteristic curve (ROC) (AUC) for microRNA-21 expression in serum or sputum as a biomarker for lung carcinoma identification. The publication bias was evaluated by Deek's funnel plot.
resultsSeventeen diagnostic studies were finally included and made data pooling. For the included 17 studies, 4 investigated the microRNA-21 expression in sputum and 13 studies in serum. The pooled diagnostic sensitivity and specificity were 0.73 (95% CI, 0.67-0.78) and 0.81 (95% CI, 0.75-0.85), respectively, under random effect model. The combined DOR was 9.65 (95% CI, 6.64-14.03) with the AUC of 0.84 (95% CI, 0.80-0.87). Given a pre-test probability of 50%, the post-test positive probability and post-test negative probability were 79% and 25%, respectively, by using microRNA-21 as a biomarker for lung carcinoma diagnosis. Deek's funnel was obviously asymmetry and indicated significant publication bias (p < 0.05).
conclusionMicroRNA-21 in serum or sputum was a promising biomarker for lung cancer identification with relative high diagnostic sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.